Repository logo
 

DNA repair. PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair.


Type

Article

Change log

Authors

Ochi, Takashi 
Blackford, Andrew N 
Coates, Julia 
Jhujh, Satpal 
Mehmood, Shahid 

Abstract

XRCC4 and XLF are two structurally related proteins that function in DNA double-strand break (DSB) repair. Here, we identify human PAXX (PAralog of XRCC4 and XLF, also called C9orf142) as a new XRCC4 superfamily member and show that its crystal structure resembles that of XRCC4. PAXX interacts directly with the DSB-repair protein Ku and is recruited to DNA-damage sites in cells. Using RNA interference and CRISPR-Cas9 to generate PAXX(-/-) cells, we demonstrate that PAXX functions with XRCC4 and XLF to mediate DSB repair and cell survival in response to DSB-inducing agents. Finally, we reveal that PAXX promotes Ku-dependent DNA ligation in vitro and assembly of core nonhomologous end-joining (NHEJ) factors on damaged chromatin in cells. These findings identify PAXX as a new component of the NHEJ machinery.

Description

Keywords

Antigens, Nuclear, Cell Line, Tumor, Crystallography, X-Ray, DNA Breaks, Double-Stranded, DNA End-Joining Repair, DNA Repair Enzymes, DNA-Binding Proteins, Humans, Ku Autoantigen, Protein Structure, Secondary, RNA Interference

Journal Title

Science

Conference Name

Journal ISSN

0036-8075
1095-9203

Volume Title

347

Publisher

American Association for the Advancement of Science (AAAS)
Sponsorship
Cancer Research Uk (None)
European Research Council (268536)
Wellcome Trust (092096/Z/10/Z)
Wellcome Trust (093167/Z/10/Z)
Cancer Research Uk (None)
Cancer Research Uk (None)
Cancer Research UK (18796)
T.O. and T.L.B. are supported by the Wellcome Trust. The Jackson lab is funded by Cancer Research UK (CRUK) program grant C6/A11224, the European Research Council and the European Community Seventh Framework Programme grant agreement no. HEALTH-F2-2010- 259893 (DDResponse). Core infrastructure funding to the Jackson lab is provided by CRUK (C6946/A14492) and the Wellcome Trust (WT092096). S.P.J. receives his salary from the University of Cambridge, supplemented by CRUK. V.M.D. is a CRUK Career Development Fellow. The Draviam lab is funded by a CRUK CDA (C28598/A9787).